DiagnoCure Inc.

March 15, 2007 15:21 ET

DiagnoCure Announces $25,155,000 Bought Deal

QUEBEC, QUEBEC--(CCNMatthews - March 15, 2007) -


DiagnoCure Inc. (TSX:CUR) today announced that it has entered into an agreement for a $25,155,000 bought deal financing with a syndicate of underwriters led by National Bank Financial Inc. A total of 5,850,000 common shares will be issued at a price of $4.30 per common share. The proceeds from the offering will be used to support the implementation of the company's business plan, namely to expand the product portfolio and acquire or in-license additional cancer diagnostic products.

The underwriters will also have an over-allotment option, exercisable at any time until up to 30 days following the Closing of the financing, to purchase up to an additional 877,500 common shares on the same terms and conditions which would increase the total amount to $28,928,250. The offering is subject to normal regulatory approvals including approval of the Toronto Stock Exchange and is expected to close on or before April 3, 2007.

The securities offered have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States absent registration or an exemption from the registration requirements thereunder. This release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

About DiagnoCure

DiagnoCure specializes in the development, production and commercialization of molecular diagnostics for the detection and management of cancer. Its first test, ImmunoCyt™ / uCyt+™ for bladder cancer, is distributed worldwide. In 2003, the Company entered into a strategic alliance with Gen-Probe for the development and commercialization of a second generation PCA3-based diagnostic test for prostate cancer. This test is now available in analyte specific reagent (ASR) format in the U.S. as well as in Europe with full CE Mark. The Company plans to expand its product portfolio, namely in prostate, lung and other cancers. In addition to its own research, the Company intends to acquire or in-license promising cancer biomarkers from both academic and commercial institutions. Additional information can be found at www.diagnocure.com.

Statements made in this news release, other than those concerning historical financial information, should be considered forward-looking and subject to various risks and uncertainties. Such forward-looking statements are based on management's beliefs and assumptions regarding the information currently available. The Company's actual results could differ materially from those expressed in the forward-looking statements. Factors that could cause results to vary include, among other things, those described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward-looking statements contained herein.

Contact Information